SynBioBeta Speaker
Amy Locks
Anzen Industries
CEO
Amy is the co-founder and CEO of Anzen Industries, a cell-free manufacturing company developing modular enzyme reactors to produce high-value chemicals. Anzen vertically integrates enzyme design, stabilisation and reactor engineering to enable more resilient and capital-efficient chemical manufacturing.Amy has a PhD in enzyme stabilisation from University College London, where she focused on rapid methods for enzyme durability and reusability. Anzen has raised $2.2M in pre-seed funding and is relocating to California to scale its technology and team.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Amy
This Year
•
-
Planetary Health
Biology Without Cells: The Rise of Cell-Free Biomanufacturing
Cell-free systems are redefining what’s possible in bioproduction. By bypassing the complexity of living cells, innovators can run enzyme cascades, prototype metabolic pathways, and produce high-value molecules with unmatched speed, precision, and purity. This new class of systems—from freeze-dried reactions to continuous cell-free reactors—enables rapid iteration, on-demand production, and scalable biochemistry without the need for fermentation tanks or long development cycles.
Get a Ticket
Featuring
Kavya Sharman
Phase Capital
Managing Partner
Amy Locks
Anzen Industries
CEO
Enzyme-stabilization expert building cell-free modular “enzyme reactors.”
Ravit Netzer
Scala Biodesign
CEO & Co-founder
Christopher Pirie
Decycle Bio
CEO
De-novo, cell-free enzyme cascades converting waste into chemicals
Neeka Mashouf
Rubi Laboratories
CEO and Co-founder
•
-
Planetary Health
Biology Without Cells: The Rise of Cell-Free Biomanufacturing
Cell-free systems are redefining what’s possible in bioproduction. By bypassing the complexity of living cells, innovators can run enzyme cascades, prototype metabolic pathways, and produce high-value molecules with unmatched speed, precision, and purity. This new class of systems—from freeze-dried reactions to continuous cell-free reactors—enables rapid iteration, on-demand production, and scalable biochemistry without the need for fermentation tanks or long development cycles.
Get a Ticket
Featuring
Kavya Sharman
Phase Capital
Managing Partner
Amy Locks
Anzen Industries
CEO
Enzyme-stabilization expert building cell-free modular “enzyme reactors.”
Ravit Netzer
Scala Biodesign
CEO & Co-founder
Christopher Pirie
Decycle Bio
CEO
De-novo, cell-free enzyme cascades converting waste into chemicals
Neeka Mashouf
Rubi Laboratories
CEO and Co-founder
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
